

&lt;1&gt; = &lt;for oral administration&gt;

25

## CLAIMS

1. ~~Orally administered~~ Tablet<sup><1></sup> that disintegrates quickly in the oral cavity in less than 30 seconds, comprising:

i) Spray-dried mannitol in a proportion of at least 59.5%;

ii) active ingredient in a proportion below or equal to 10%, as a fine powder in which at least 90% in 10 weight of the active ingredient has a particle size less than 100 µm;

iii) Microcrystalline cellulose in a proportion from 10 to 18%, with an average particle size of approximately 50 µm where at least 99% in weight of 15 microcrystalline cellulose has a particle size below 250 µm;.

iv) Sodium croscarmellose in a proportion from 1 to 4%; and

v) A lubricant agent in a proportion from 0.5 to 20 2% in weight,

where, unless specified otherwise, the percentages are expressed in weight of the total weight of the tablet.

2. ~~Orally administered~~ Tablet<sup><1></sup> according to claim 25 1, characterised in that it has a friability below 0.5% according to Ph. Eur. 2.9.7.

3. ~~Orally administered~~ Tablet<sup><1></sup> according to claim 2, characterised in that it has a friability below 0.2% 30 according to Ph. Eur. 2.9.7.

4. ~~Orally administered~~ Tablet<sup><1></sup> according to claim 1, characterised in that it has an apparent density from 1.1 to 1.3 g/ml.

35

5. ~~Orally administered~~ <sup>T</sup> <sup><1></sup> tablet according to claim 1, characterised in that it has a flavouring agent in a proportion from 0.5 to 2% in weight of the total weight of the tablet.

5

6. ~~Orally administered~~ <sup>T</sup> <sup><1></sup> tablet according to claim 5, characterised in that it has an artificial sweetener in a proportion from 0.5 to 2% in weight of the total weight of the tablet.

10

7. ~~Orally administered~~ <sup>T</sup> <sup><1></sup> tablet according to claim 1, characterised in that it has a humidity adsorbing agent in a proportion from 0.1 to 0.5% in weight of the total weight of the tablet.

15

8. ~~Orally administered~~ <sup>T</sup> <sup><1></sup> tablet according to claim 1, characterised in that it has an anti-adherent agent in a proportion from 0.5 to 2% in weight of the total weight of the tablet.

20

9. ~~Orally administered~~ <sup>T</sup> <sup><1></sup> tablet according to claim 1, characterised in that the proportion of insoluble elements is below 20% in weight of the total weight of the tablet.

25

10. ~~Orally administered~~ <sup>T</sup> <sup><1></sup> tablet according to any of previous claims, characterised in that it has a round shape, flat, bevelled with a thickness from 1,8 to 2.2 mm.

30

11. ~~Orally administered~~ <sup>T</sup> <sup><1></sup> tablet according to claim 10, characterised in that it disintegrates quickly in the oral cavity in less than 20 seconds.

12. Process for obtaining a ~~orally administered~~ <sup>T</sup> <sup><1></sup> 35 tablet as defined in any of claims 1 to 11, characterised

in that it comprises the following steps:

i) Sieving and mixing the components except for the lubricant agent;

ii) Sieving the lubricant agent;

5       iii) Mixing of all the components; and

iv) Direct compression of the final mixture.

13. Process for obtaining a tablet according to claim 12, characterised in that said final mixture has a  
10 flowability below or equal to 10 seconds according to Ph. Eur. 2.9.16.

14. Process for obtaining a tablet according to claim 12, characterised in that said final mixture has an  
15 ability to settle below or equal to 20 ml according to Ph. Eur. 2.9.15.